OR WAIT 15 SECS
Children in the United States and Canada are being vaccinated against influenza without adequate proof that it will work, concludes a study published in this weeks issue of
Children in the United States and Canada are being vaccinated against influenza without adequate proof that it will work, concludes a study published in this weeks issue of TheLancet.
Most immunization campaigns target people aged 65 years or older. The United States and Canada have recently started vaccinating children, including those aged six to 24 months, in the hope of reducing disease spread, admissions and visits to hospitals, deaths of elderly relatives, complications (such as ear infections and pneumonia), absences from school, and parental loss of workdays and over-prescribing of antibiotics. However, there is no evidence that vaccinating children can achieve these goals.
Tom Jefferson, MD (Cochrane Vaccines Field, Italy), and colleagues identified and assessed 25 comparative studies that evaluated the efficacy (reduction in laboratory confirmed case) and effectiveness (reduction in symptomatic cases) of influenza vaccines in healthy children aged 16 years or younger.
Vaccines of live viruses with weakened infectivity had 79 percent efficacy and 38 percent effectiveness in children older than two years compared with placebo or no immunization. Inactivated vaccines had a lower efficacy (65 percent) than live weakened vaccines, and in children aged two years or younger they had similar effects to placebo. Effectiveness of inactivated vaccines was about 28 percent in children older than two years. Vaccines were effective in reducing long school absences but had little effect on other outcomes, such as hospital stays and lower respiratory tract disease, when compared with placebo or no intervention. However, the authors note that these conclusions are based on a small number of studies.
We have identified a large dataset showing reasonable quality evidence of efficacy of influenza vaccines in children age two years or older, especially for two-dose live attenuated vaccines, says Jefferson. However, we noted a striking difference between efficacy and effectiveness of vaccines because of the large proportion of influenza-like illness caused by agents other than influenza viruses. This is an important point in the decision to immunize whole populations. Immunization of very young children is not lent support by our findings. Although a growing body of evidence shows effect of influenza on admissions and deaths of children, we recorded no convincing evidence that vaccines can reduce mortality, hospital admissions, serious complications and community transmission of influenza.
Source: The Lancet